MoonLake Immunotherapeutics - Class A ordinary share, par value $0.0001 per share (MLTX) Institutional Ownership

13F Institutional Holders and Ownership History from Q1 2022 to Q4 2025

Type / Class
Equity / Class A ordinary share, par value $0.0001 per share
Symbol
MLTX on Nasdaq
Shares outstanding
71,400,541
Price per share
$16.25
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
56,335,586
Total reported value
$742,544,459
% of total 13F portfolios
0%
Share change
+18,819,757
Value change
+$286,460,206
Number of holders
127
Price from insider filings
$16.25
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of MoonLake Immunotherapeutics - Class A ordinary share, par value $0.0001 per share (MLTX) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BIOTECHNOLOGY VALUE FUND L P 28% $141,616,706 19,751,284 BVF PARTNERS L P/IL 06 Nov 2025
Deep Track Capital, LP 6.5% $33,054,209 4,610,071 Deep Track Capital, LP 05 Nov 2025
Cormorant Asset Management, LP 6.1% $74,477,904 4,355,433 Cormorant Asset Management, LP 31 Dec 2025
PRICE T ROWE ASSOCIATES INC /MD/ 4.7% -12% $117,334,991 -$14,571,725 2,974,271 -11% T. Rowe Price Associates, Inc. 31 Mar 2025
Avoro Capital Advisors LLC 3.2% -48% $14,340,000 -$15,415,500 2,000,000 -52% Avoro Capital Advisors LLC 30 Sep 2025
Chen Bihua 3.1% $108,084,177 1,994,173 Chen Bihua 30 Sep 2025
FMR LLC 1.1% -88% $5,212,098 -$35,678,759 726,931 -87% FMR LLC 30 Sep 2025

As of 31 Dec 2025, 127 institutional investors reported holding 56,335,586 shares of MoonLake Immunotherapeutics - Class A ordinary share, par value $0.0001 per share (MLTX). This represents 79% of the company’s total 71,400,541 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of MoonLake Immunotherapeutics - Class A ordinary share, par value $0.0001 per share (MLTX) together control 69% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
BVF INC/IL 28% 19,751,284 0% 8.8% $260,321,923
Deep Track Capital, LP 6.5% 4,610,071 1.4% $60,760,736
Cormorant Asset Management, LP 6.1% 4,355,433 +118% 3.3% $57,404,607
D. E. Shaw & Co., Inc. 3.5% 2,480,767 0.02% $32,696,509
JANUS HENDERSON GROUP PLC 2.9% 2,095,988 +18783% 0.01% $27,656,562
Logos Global Management LP 2.5% 1,750,000 1.5% $23,065,000
JANE STREET GROUP, LLC 2.4% 1,682,148 +7554% 0.03% $22,170,711
Balyasny Asset Management L.P. 2.2% 1,571,071 -7.5% 0.04% $20,706,716
MORGAN STANLEY 1.5% 1,044,581 +307% 0% $13,767,578
Vivo Capital, LLC 1.4% 1,000,000 0.85% $13,180,000
PRICE T ROWE ASSOCIATES INC /MD/ 1.3% 959,553 +17% 0% $12,647,000
JPMORGAN CHASE & CO 1.2% 837,739 +381% 0% $11,041,400
MILLENNIUM MANAGEMENT LLC 1.1% 802,722 +800% 0.01% $10,579,876
TWO SIGMA INVESTMENTS, LP 1.1% 784,811 +73% 0.02% $10,343,809
Point72 Asset Management, L.P. 1.1% 772,500 +7783% 0.02% $10,181,550
Nuveen, LLC 0.89% 637,434 +0.27% 0% $8,401,380
HRT FINANCIAL LP 0.89% 635,901 +344% 0.03% $8,381,000
SUSQUEHANNA INTERNATIONAL GROUP, LLP 0.77% 549,236 +182% 0.01% $7,238,930
Jefferies Financial Group Inc. 0.7% 500,000 +1900% 0.05% $6,590,000
Voleon Capital Management LP 0.7% 499,099 +1139% 0.14% $6,578,125
Jump Financial, LLC 0.6% 425,559 0.07% $5,608,868
Soleus Capital Management, L.P. 0.56% 400,000 0.22% $5,272,000
CITADEL ADVISORS LLC 0.53% 380,890 +672% 0% $5,020,130
Rhenman & Partners Asset Management AB 0.51% 364,000 +76% 0.45% $4,797,520
STEMPOINT CAPITAL LP 0.49% 348,401 0.79% $4,591,925

Institutional Holders of MoonLake Immunotherapeutics - Class A ordinary share, par value $0.0001 per share (MLTX) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 56,335,586 $742,544,459 +$286,460,206 $13.18 127
2025 Q3 37,454,837 $268,355,896 -$543,765,841 $7.17 132
2025 Q2 58,588,386 $2,765,378,029 -$36,637,296 $47.20 129
2025 Q1 59,723,013 $2,333,397,891 -$153,122,113 $39.07 134
2024 Q4 63,244,825 $3,424,722,298 +$68,390,992 $54.15 114
2024 Q3 62,105,859 $3,131,140,770 +$81,133,174 $50.42 108
2024 Q2 60,656,094 $2,667,012,692 +$45,095,266 $43.97 109
2024 Q1 59,346,206 $2,980,958,004 +$1,466,170 $50.23 112
2023 Q4 58,433,271 $3,528,831,635 +$147,969,282 $60.39 124
2023 Q3 56,323,727 $3,210,450,399 +$46,563,145 $57.00 118
2023 Q2 56,057,516 $2,858,934,462 +$861,230,424 $51.00 82
2023 Q1 39,419,149 $843,176,754 +$59,244,738 $21.39 43
2022 Q4 37,748,780 $396,358,589 +$8,234,061 $10.50 32
2022 Q3 36,855,847 $291,356,995 +$3,123,162 $7.76 24
2022 Q2 36,470,008 $190,106,000 +$182,848,000 $5.25 22
2022 Q1 653,872 $7,258,000 +$7,258,000 $11.10 1